Latest news with #FSP
Al Etihad
11-06-2025
- Business
- Al Etihad
Global investment management firm Harrison Street opens office at ADGM
11 June 2025 09:47 A. SREENIVASA REDDY (ABU DHABI)Harrison Street, a leading global investment management firm specialising in alternative real assets, has formally expanded into the Middle East with the launch of a new office at the Abu Dhabi Global Market (ADGM).The firm has secured a Financial Services Permission (FSP) from the Financial Services Regulatory Authority (FSRA) of ADGM, enabling it to provide regulated services from its Abu Dhabi base. Headquartered in Chicago and London, Harrison Street also maintains offices across North America, Europe and Asia.'This strategic initiative aims to bolster Harrison Street's ability to advise and collaborate with investors in the Middle East,' the company said in a statement. 'This comes at a time when regional investors increasingly seek economic diversification and a broader range of international investment opportunities, including global real assets exposure.'The new office will be led by Hadi Nasser, who joined Harrison Street in March 2024 as Managing Director and Head of Investor Relations – Middle East. Nasser, who has nearly two decades of experience in capital raising and advisory roles across Europe and the Middle East, previously held roles at Rockpoint and EnTrust Global. He will be responsible for developing and maintaining Harrison Street's institutional relationships across the Gulf region.'We are excited to now formalise our presence in the Middle East, and specifically within ADGM, an increasingly important hub for the global investment management industry,' said Christopher Merrill, Co-Founder, Chairman and CEO of Harrison Street. 'This strategic expansion aligns with the Middle East's advanced investment landscape and its appetite for diversified, alternative sectors.'Arvind Ramamurthy, Chief Market Development Officer of ADGM, welcomed the development: 'Harrison Street brings valuable expertise and innovation to our thriving financial centre. Their presence further strengthens ADGM's position as a leading hub for asset and wealth management.'Founded in 2005, Harrison Street has invested over $71 billion across key sectors including senior housing, student housing, build-to-rent, healthcare delivery, life sciences, storage real estate, and digital infrastructure. The firm's strategy is supported by long-standing partnerships with more than 60 operating partners, 200 universities, and 30 top health his 2024 annual letter to investors, Merrill described the past year as a 'year of transition,' highlighting the firm's repositioning in response to macroeconomic volatility. During 2024, Harrison Street committed $5 billion to new investments and sold $4 billion worth of assets across 81 properties, including off-market transactions in student and senior housing, data centres, and medical offices. He also emphasised the firm's increasing adoption of AI and data analytics in its investment approach, and maintained a strong long-term outlook for alternative real assets. Harrison Street's new office, located at Al Sila Tower in ADGM, will serve as a regional base to guide institutional clients through a period marked by repricing and a recovering flow of capital into global real estate and infrastructure markets.
Irish Independent
11-06-2025
- Business
- Irish Independent
International financial institutions build stakes in Dalata
The latest to declare a holding in the company was Barclays, the British bank, which has bought almost 1.7 million shares, giving it a 0.8pc stake. It joined BNP Paribas, the French bank, which disclosed yesterday that it had both shares and short positions in Dalata. According to its filing with the Irish Takeover Panel, the bank now holds just over 5.2 million shares, a 2.5pc stake. It reduced its short positions by 355,653 shares. Short selling means borrowing shares whose price you think will fall and selling them. The intention is to buy the stock back at a lower price, return the borrowed stock, and pocket the profits. Societe Generale, another French bank, has also declared its ownership and short positions in Dalata. In its filing to the regulatory authorities, Societe Generale disclosed it has a total interest of almost 5.2 million shares, equal to a 2.45pc stake. Its short positions are relatively small – amounting to 0.03pc of the stock. Goldman Sachs has already increased its voting rights in Dalata to 4.83pc. State Street Global Advisors has a stake of just over 1pc. Fil Ltd and its subsidiaries have disclosed a 6.3pc stake in Dalata, which owns 55 hotel properties in Britain and Ireland and is listed on the stock exchanges in London and Dublin. In a filing by Davy Stockbrokers, it declared both purchases and sales of shares of Dalata, saying it had bought 71,206 at prices ranging from €6.25 to €6.35, and sold 74,579 shares at prices from €6.27 to €6.37. Dalata's share price reached €6.43 just after midday yesterday, its highest point in over a year, before falling back in afternoon trading. There were over 350,000 shares worth over €2.2m traded throughout the day. Last week Dalata, whose chief executive is Dermot Crowley, rejected a €1.3bn offer from a Scandinavian consortium, saying it materially undervalued the group. The offer of €6.05 a share by Pandox and Eiendomsspar represented a premium of just over 27pc on the €4.76 closing price of March 5, the last trading day before Dalata announced it was launching a strategic review, with one option being a sale. In an announcement made within hours of the offer being notified, Dalata rejected it, a move that has been vindicated by the subsequent surge in the company's share price. 'The board announced a strategic review on March 6 to explore options available to optimise capital opportunities for the group and to enhance value for shareholders, including a Formal Sales Process (FSP) pursuant to the Irish takeover rules,' it said in a statement. 'The board continues to engage in constructive discussions with a number of parties who are participating in the FSP and who have submitted initial non-binding proposals to acquire the entire issued and to-be-issued share capital of the group.' Yesterday, a spokeswoman for Dalata said there was no update on this position. Under takeover rules, the Scandinavian consortium has until July 15 to either announce a binding intention to make a bid for Dalata, or to pull out.
Yahoo
05-06-2025
- Entertainment
- Yahoo
19 tough Delaware concerts for June 2025
Get ready to weather a musical storm since Delaware is about to get drenched in concerts this June. Here's your forecast of 19 must-see shows sweeping through the Small Wonder all month long. Subscribe to DO Delaware Folks with an appetite for emo/pop punk tunes will get served a casserole of it when The Warped Tour Band takes you on a blast to the past to dish up some of the catchiest tunes in that genre, over the last three decades. Bottle & Cork (1807 Highway One, Dewey Beach) at 8:30 p.m. June 6. Tickets are $25. Visit or call (302) 227-7272. 21 things Delaware beaches for more fun: Beach concerts, swim-up bars, IMAX & more Jennifer Westrip isn't scared to let the "Sparks Fly" all over Delaware's premiere theater when she attempts to save revelers from a hot and humid "Cruel Summer" with her show "Fearless: The Taylor Swift Experience." If Westrip's mannerisms look eerily similar to T-Swift, it might have something to do with the fact that the tribute artist is a singer who also has a theater background. "The Taylor Swift Experience" offers Swift's greatest hits and the tribute show is branded as the best in the country. The Grand (818 N. Market St., Wilmington) at 8 p.m. June 7. Tickets are $42-$52. Visit or call (302) 652-5577. Blues brothers Taj Mahal and Keb' Mo' will tour to lower Delaware with their new album, "Room On The Porch." The project drops May 23. The upcoming project comes nearly a decade after the pair released their collaborative album "TajMo," which won a Grammy Award for Best Contemporary Blues Album. Freeman Arts Pavilion (31806 Lakeview Drive, near Selbyville) at 7 p.m. June 7. Tickets for general admission are $59, plus fees. Visit or call (302) 436-3015. The darling Sussex County band The Funsters will turn up at Rocking the Docks summer concert series with a benefit show to support the Fourth Street Preserve (FSP). This historic forest in Lewes is in need of permanent protection. To achieve this, organizers need to raise $8 million by Sept. 15, according to FSP's website. Local act the Williams Brothers will open the concert. Lewes Ferry Grounds (43 Cape Henlopen Dr., Lewes) at 3 p.m. June 8. Tickets are $44.02 to $87.54. For more info, visit Bring an umbrella, because the emo band Sunny Day Real Estate likely will rain down nostalgic tunes from their '90s catalog when they tour to the First State. Two of their most notable songs are "In Circles" and "Seven." But that's not to take away from the band's 2024 album, "Diary at London Bridge Studio." Cloud Nothings will open this show. The Queen (500 N. Market St., Wilmington) at 7:30 p.m. June 8. Tickets are $47-$107. Visit or call (302) 400-7020. This rock band from Philly has had the attention of Rolling Stone for years. This summer, frontman Adam Weiner, who grew up in South Jersey, and the ensemble are gonna have a captive audience in Lewes at Rock the Docks concert series. Low Cut Connie is known for songs like 'Private Lies' and 'Boozophilia.' Lewes Ferry Grounds (43 Cape Henlopen Dr., Lewes) at 6 p.m. June 12. Tickets for general admission are $35 (processing and customer fees are $9.02). Visit Rolling Stone has recognized the whirlwind success of Kanin Wren's Taylor Swift tribute. It was during Wren's junior year in high school when a consultant suggested she start a Taylor Swift tribute, despite the singer-songwriter being hesitant to make the leap. In 2024, Wren ended up selling out amphitheaters and performing in 15 states, according to her bio. To elevate the Taylor Swift experience, the rising tribute artist Wren has been known to play with a full band. Milton Theatre (110 Union St., Milton) 8 p.m. June 12. Tickets are $36-$45. Visit or call (302) 684-3038. It'll be a night to remember when David Foster, Katharine McPhee (Foster's wife) and Chris Botti hit the stage at the Freeman Arts Pavilion. Foster is one of the most decorated composers of our time and has 16 Grammys under his belt (two more than Taylor Swift). Meanwhile, Katharine McPhee rose to fame on Season 5 of "American Idol." Finally, the Grammy-winning trumpeter Chris Botti has been one of the most popular instrumentalists in the world, and he'll show off his skills in SoDel this summer. General admission guests may bring their own chain to this concert. Freeman Arts Pavilion (31806 Lakeview Drive, near Selbyville) at 7 p.m. June 13. Tickets start at $62.64 (including $8.64 service charge). Visit or call (302) 436-3015. Hailing from York, Pennsylvania, The Wild Hymns are a husband-and-wife duo who weave a soundscape of folk-pop, and dreamy art-rock into a tapestry of mellow Americana. Megan Woodland and Jeff Hewitt both mean business on stage, but in an artful way. Dogfish Head Brewings & Eats (320 Rehoboth Ave., Rehoboth Beach) from 9-11 p.m. June 14. Visit or call (302) 226-2739. The famous Wooten Brothers bring their homemade flavor to the Clifford Brown Jazz Festival. The band, which has been a musical force for over five decades, consists of Regi (guitar/vocals), Roy (drums/vocals), Joseph (keyboards/vocals) and Victor (bass/vocals). Rolling Stone ranked Victor, the youngest of the siblings, at No. 10 for the "Top Ten Bassists of All Time" in 2011. That list included The Beatles' Paul McCartney (No. 3) and John Entwistle of The Who (No. 1). Rodney Square (1000 N. Market St., Wilmington) on June 19. Free event. Visit After supporting Rascal Flats on a reunion tour, country star Chris Lane will headline a beach concert for his SoDel fans. The former college baseball player has managed to hit a bunch of homeruns with favorites like "I Don't Know About You," "Take Back Home Girl" and "Big, Big Plans." Bottle & Cork (1807 Highway One, Dewey Beach) at 8 p.m. June 19. Tickets are $40 in advance; $43 day of show. Visit or call (302) 227-7272. R&B star Eric Benét will bring his talents up after headlining the Rehoboth Beach Jazz Festival in 2023. He dropped his new song "Can't Wait," featuring Keri Hilson. The '90s star is known for tunes like "Spend My Life With You," "Georgy Porgy" and "Sometimes I Cry." Rodney Square (1000 N. Market St., Wilmington) on June 20. Free event. Visit Another R&B legend set to play the Clifford Brown festival is Chantė Moore, who made a name for herself the 1990s, and is celebrated for hit songs like "I Love You," "Candlelight & You," and "Chante's Got A Man." Rodney Square (1000 N. Market St., Wilmington) on June 20. Free event. Visit The Grammy Award-winning blues guitarist Christone "Kingfish" Ingram is on of the hottest names in the game, and for good reason. The blues star has captivated fans both in person and online with performance videos buzzing on social media. A decade ago, as a teenager, Kingfish displayed his extraordinary talent through videos on his YouTube channel. Freeman Arts Pavilion (31806 Lakeview Drive, near Selbyville) at 7 p.m. June 20. Tickets are $29, plus fees. Visit or call (302) 436-3015. Tickets are now on sale for Jimmie Allen's concert at Bally's Dover Casino Resort on June 20. Bally's Dover Casino Resort is a departure from his usual concerts farther south in the state that offer a beach and bar vibe. The Dover location holds personal significance for the Delaware country star since Allen once briefly was a student at Delaware State University, before he became famous. Bally's Dover Casino Resort (1131 N. Dupont Highway, Dover) at 9 p.m. June 20. Tickets are $75-$150. For more info, visit Elements of rock, hip-hop and reggae appear in 311's music. The beloved band from the '90s and early 2000s is responsible for big tunes like "Amber," "Beautiful Disaster" and "Love Song." Freeman Arts Pavilion (31806 Lakeview Drive, near Selbyville) at 6 p.m. June 21. Tickets are $69, plus fees. Visit or call (302) 436-3015. The alt-rock piano star Ben Folds is regarded as one of the most influential musicians of this generation. He's acclaimed for tunes like "Brick," "Heist" and "You Don't Know Me." The Grand (818 N. Market St., Wilmington) at 7 p.m. June 22. Tickets are $79-$115. Visit or call (302) 652-5577. This cover band has a big following. The gang is known to sell out shows at Rocking the Docks in Lewes, which will probably happen again this summer. The Amish Outlaws feature members who perform in Amish attire. Some of the members grew up in the community before deciding to rebel and leave their community to live in the secular world. Lewes Ferry Grounds (43 Cape Henlopen Drive, Lewes) at 6 p.m. June 25. Tickets for general admission are $35 (processing and customer fees are $9.02). Visit Siblings John and TJ Osborne are best known as the Brothers Osborne, a pair of Grammy winners who grew up in Maryland. The bros have released favorites like "It Ain't My Fault," "Stay A Little Longer" and "Rum." Freeman Arts Pavilion (31806 Lakeview Drive, near Selbyville) at 7 p.m. June 26. Tickets are $59-$109, plus fees. Visit or call (302) 436-3015. Longwood Gardens music in 2025: It wants to plant a musical kiss on you this summer If you have an interesting story idea, email lifestyle reporter Andre Lamar at alamar@ Consider signing up for his weekly newsletter, DO Delaware, at This article originally appeared on Delaware News Journal: 19 can't-miss Delaware concerts for June 2025
Irish Independent
03-06-2025
- Business
- Irish Independent
Dalata rejects takeover bid
The offer of €6.05 per share by Pandox and Eiendomsspar represented a premium of just over 27pc on the €4.76 closing price of March 5, the last trading day before Dalata announced it was launching a strategic review, with one option being a sale. It was a 14pc premium to the three-month average price of €5.32 per share. In an announcement made within hours of the offer being notified, Dalata said it had considered the bid, along with its advisers, and was rejecting it. 'The board announced a strategic review on 6 March to explore options available to optimise capital opportunities for the group and to enhance value for shareholders, including a Formal Sales Process (FSP) pursuant to the Irish takeover rules,' it said in a statement. 'The board continues to engage in constructive discussions with a number of parties who are participating in the FSP and who have submitted initial non-binding proposals to acquire the entire issued and to-be-issued share capital of the group. Pandox is not a participant in the FSP, having declined to enter the process on the terms set out.' Dalata said its board remains committed to the ongoing process, and a further announcement will be made in due course as appropriate. Shareholders were advised to take no action in relation to the Pandox offer. Russ Mould, an analyst with AJ Bell, had pointed out that the consortium's 27.1pc bid premium was below the 36pc average on UK-listed takeovers so far this year. 'That leaves scope for someone else to come along and offer slightly more,' he said. A number of American investment firms have already submitted bids for Dalata, according to reports by Green Street, a property news website. They are said to include Bain, Apollo and Starwood, which already owns 2.7pc of Dalata through an affiliate. The board of Dalata has hired Rothschild, an investment bank, to carry out the strategic review. The company is listed in Dublin and London, and its share price was boosted by the announcement of the bid. It was up over 8pc in London, to £5.10, and by over 5pc on Euronext in Dublin, reaching €6.07 at lunchtime. Eiendomsspar, one of the largest property owners in Norway, with its portfolio including 11 hotels, already has an 8.8pc stake in Dalata. It controls 36pc of the shares in Pandox, a Swedish firm that owns 163 hotels across 11 countries in Europe, with about 36,000 rooms. Based in Stockholm, Pandox develops and then leases hotels to operators under long-term deals. Its hotels in Ireland operate under the Leonardo brand. 'As established hotel investors with deep knowledge of the European hotel sector and experience in successfully executing similar transactions in the UK and Ireland, the consortium is well positioned to support Dalata's business and long-term growth ambitions,' it said in an announcement to the stock exchange. 'The consortium is currently negotiating with a reputable European hotel operator to enter into a framework agreement for the operation of the Dalata hotels if the consortium acquires Dalata. This operator shares the consortium's commitment to long-term profitability and sustainable growth.' Under takeover rules, the consortium has until July 15 to either announce a binding intention to make a bid for Dalata, or to pull out. Dalata, whose chief executive is Dermot Crowley and which was established in 2007, has a portfolio of 55 hotels in Ireland and Britain, both owned and leased, operating under the Maldron and Clayton brands.
Business Upturn
30-05-2025
- Business
- Business Upturn
Cytek® Biosciences Is Setting the New Standard for Full Spectrum Flow Cytometry with the New Cytek Aurora™ Evo Flow Cytometer
FREMONT, Calif., May 29, 2025 (GLOBE NEWSWIRE) — In a move that underscores its dedication to shaping the future of cell analysis, Cytek Biosciences, Inc. (Nasdaq: CTKB) today announced the launch of the Cytek Aurora™ Evo system, a new full spectrum flow cytometer that improves on its flagship Cytek Aurora system. First launched in 2017 to address the limitations of existing flow cytometry technologies, Cytek's Full Spectrum Profiling™ (FSP®) systems have become the spectral technology of choice for researchers worldwide, with over 2,600 peer-reviewed publications citing its use – more than any other spectral flow cytometer. Building on this groundbreaking success, the new Cytek Aurora Evo system has been reengineered to carry forward the proven reliability and reproducibility of the Cytek Aurora system, while introducing high-throughput and automation capabilities to meet the demands of modern research. The Cytek Aurora Evo system utilizes Cytek's FSP technology, continuing to provide the field-tested capability to run large multicolor experiments without compromising data quality, as well as an unparalleled level of assay flexibility. The ability to resolve both small particles and large cells on a single instrument allows scientists to tackle a wider range of applications with confidence. The newly added capabilities of improved sample throughput, automated instrument maintenance, and data harmonization were all added to empower researchers to accelerate discoveries with greater speed and confidence. With increasing demand for high-performance, flexible, and efficient cell analysis tools, the new Cytek Aurora Evo flow cytometer is well-positioned to meet the evolving needs of researchers and further drive the adoption of spectral flow cytometry. Key features and benefits of the new system include: Instrument Standardization: Harmonized instruments allow for consistent, accurate and reproducible biological data across systems, labs and time. Harmonized instruments allow for consistent, accurate and reproducible biological data across systems, labs and time. High-Resolution and Throughput: A unique optical and electronics design enables excellent sensitivity and resolution across flow rates, from low (15 µL/min) to max (200 µL/min). Samples can now be acquired 2x faster than before. A unique optical and electronics design enables excellent sensitivity and resolution across flow rates, from low (15 µL/min) to max (200 µL/min). Samples can now be acquired 2x faster than before. Small Particle Detection : Previously available as an optional upgrade on the Cytek Aurora system, this capability is now built into the new Cytek Aurora Evo flow cytometer, enabling researchers to detect and resolve extracellular vesicles, viruses, bacteria and other nanoparticles. : Previously available as an optional upgrade on the Cytek Aurora system, this capability is now built into the new Cytek Aurora Evo flow cytometer, enabling researchers to detect and resolve extracellular vesicles, viruses, bacteria and other nanoparticles. Automation Capabilities: Minimize instrument maintenance and maximize efficiency. An integrated plate loader supports multiple carrier types, offering flexible user modes for both low carryover and high-throughput needs. Automated startup and shutdown further streamline workflows, reducing downtime while ensuring high-quality, high-resolution data. Recognized as a pioneer in spectral flow cytometry, Cytek's distinctive approach is renowned for its profound influence on advancing the understanding of cell biology, immunology, oncology and targeted therapeutic methodologies. 'Cytek's Aurora and Northern Lights™ systems have helped revolutionize immunology research and single-cell analysis,' said Ming Yan, Ph.D., CTO of Cytek Biosciences. 'Over the years, we have continuously pushed the boundaries of what's possible in spectral flow cytometry. With this latest launch of the Cytek Aurora Evo system, we've integrated these advancements into a powerful, high-throughput workhorse that delivers an unmatched combination of performance, reliability, efficiency and ease of use – enabling more scientists to leverage the full potential of spectral flow cytometry.' The Cytek Aurora Evo system will make its public debut at CYTO 2025, with demonstrations taking place in Cytek's booth. For more information, please visit About Cytek Biosciences, Inc. Cytek Biosciences (Nasdaq: CTKB) is a leading cell analysis solutions company advancing the next generation of cell analysis tools by delivering high-resolution, high-content and high-sensitivity cell analysis utilizing its patented Full Spectrum Profiling™ (FSP®) technology. Cytek's novel approach harnesses the power of information within the entire spectrum of a fluorescent signal to achieve a higher level of multiplexing with precision and sensitivity. Cytek's platform includes: its core FSP instruments, the Cytek Aurora™, Northern Lights™, Cytek Aurora™ CS and Cytek Aurora™ Evo systems; the Cytek Orion™ reagent cocktail preparation system; the Enhanced Small Particle™ (ESP™) detection technology; the flow cytometers and imaging products under the Amnis® and Guava® brands; and reagents, software and services to provide a comprehensive and integrated suite of solutions for its customers. Cytek is headquartered in Fremont, California with offices and distribution channels across the globe. More information about the company and its products is available at Cytek's products are for research use only and not for use in diagnostic procedures (other than Cytek's Northern Lights-CLC system and certain reagents, which are available for clinical use only in China and the European Union). Cytek, Full Spectrum Profiling, FSP, Cytek Aurora, Northern Lights, Enhanced Small Particle, ESP, Cytek Orion, Amnis, Guava and Muse are trademarks of Cytek Biosciences, Inc. In addition to filings with the Securities and Exchange Commission (SEC), press releases, public conference calls and webcasts, Cytek uses its website ( LinkedIn page and X (formerly Twitter) account as channels of distribution of information about its company, products, planned financial and other announcements, attendance at upcoming investor and industry conferences and other matters. Such information may be deemed material information and Cytek may use these channels to comply with its disclosure obligations under Regulation FD. Therefore, investors should monitor Cytek's website, LinkedIn page, and X account in addition to following its SEC filings, news releases, public conference calls and webcasts. Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 as contained in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are subject to the 'safe harbor' created by those sections. All statements other than statements of historical facts are forward-looking statements. In some cases, you can identify forward-looking statements because they contain words such as 'anticipate,' 'believe,' 'contemplate,' 'continue,' 'could,' 'estimate,' 'expect,' 'intend,' 'may,' 'plan,' 'potential,' 'predict,' 'project,' 'should,' 'target,' 'will,' or 'would' or the negative of these words or other similar terms or expressions. These forward-looking statements include statements regarding Cytek's business strategies, product plans and expectations, and market opportunities. These statements are based on management's current expectations, forecasts, beliefs, assumptions and information currently available to management. These statements also deal with future events and involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. Factors that could cause actual results to differ materially include global geopolitical, economic and market conditions; Cytek's ability to manage the impacts of recent and future export controls and licensing requirements, tariffs and NIH funding policies on its business; Cytek's ability to evaluate its prospects for future viability and predict future performance; Cytek's ability to accurately forecast customer demand and adoption of its products; Cytek's ability to recognize the anticipated benefits of collaborations; Cytek's dependence on certain sole and single source suppliers; competition; market acceptance of Cytek's current and potential products; Cytek's ability to manage the growth and complexity of its organization, maintain relationships with customers and suppliers and hire and retain key employees; Cytek's ability to manufacture its products in high-quality commercial quantities successfully and consistently to meet demand; Cytek's ability to increase penetration in its existing markets and expand into adjacent markets; Cytek's ability to secure additional distributors or maintain good relationships with its existing distributors; Cytek's ability to successfully develop and introduce new products; Cytek's ability to maintain, protect and enhance its intellectual property; Cytek's ability to continue to stay in compliance with its material contractual obligations, applicable laws and regulations; and foreign currency exchange impacts. You should refer to the section entitled 'Risk Factors' set forth in Cytek's Quarterly Report on Form 10-Q filed on May 8, 2025 with the SEC, and other filings Cytek makes with the SEC from time to time for a discussion of important factors that may cause actual results to differ materially from those expressed or implied by Cytek's forward-looking statements. Although Cytek believes that the expectations reflected in the forward-looking statements are reasonable, it cannot provide any assurance that these expectations will prove to be correct nor can it guarantee that the events and circumstances reflected in the forward-looking statements will occur. The forward-looking statements in this press release are based on information available to Cytek as of the date hereof, and Cytek disclaims any obligation to update any forward-looking statements provided to reflect any change in its expectations or any change in events, conditions, or circumstances on which any such statement is based, except as required by law. These forward-looking statements should not be relied upon as representing Cytek's as of any date subsequent to the date of this press release. Media Contact:Stephanie OlsenLages & Associates(949) 453-8080 [email protected]
